Regencell Bioscience Holdings Limited (RGC)
NasdaqCM · USD · Healthcare · Drug Manufacturers - Specialty & Generic
$6.87 (+1.63%) as of
Key statistics
- Market cap
- 3.41B
- EPS (TTM)
- -0.02
- Dividend yield
- 0.00%
- 52-week range
- 4.51 – 69.00
- Beta
- 1.17
- Profit margin
- 0.00%
- Volume
- 50.98k
About Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Causeway Bay, Hong Kong
- Employees
- 10
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.